Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galinpepimut-S and Nivolumab in Malignant Pleural Mesothelioma
NCT04040231Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2019
- Primary completion
- Nov 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of galinpepimut-s in malignant pleural mesothelioma (MPM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum tolerated dose at 24 months. Started Jul 2019; status: completed.
02
Drugs
galinpepimut-s
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04040231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040231.